The amount of C1q–adiponectin complex is higher in the serum and the complex localizes to perivascular areas of fat tissues and the intimal–medial layer of blood vessels of coronary artery disease patients

Cardiovascular Diabetology

Sung Hee Choi²  Hak Chul Jang²  Kyong Soo Park²  Soo Lim²  Jae Hoon Moon²  Kyoung Min Kim²  Eu Jeong Ku¹  Hye Yeon Choi¹  Cheong Lim³  Eun Shil Hong¹ 

[1] Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, 300, Gumi-dong, Bundang-gu, Seongnam 463-707, South Korea;Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea;Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea

关键词: Biomarker;    Coronary artery disease;    High-molecular weight adiponectin;    Adiponectin;    C1q;   

Others  :  1208995
DOI  :  10.1186/s12933-015-0209-0

 received in 2015-01-23, accepted in 2015-04-09,  发布年份 2015

【 摘 要 】

Background

The complement component C1q triggers activation of the classical immune pathway and can bind to adiponectin (APN). Recently, some studies have been reported that serum C1q-APN/total APN ratio correlates with atherosclerosis and coronary artery disease (CAD). We assessed the relationships between C1q related variables and the severity of CAD, and investigated the localization of the C1q–APN complex.

Methods

The sample included 153 subjects comprising healthy controls and patients with subclinical or overt CAD. We measured the serum concentrations of C1q, total APN, and high-molecular weight (HMW)-APN, and the amount of C1q–APN complex. We identified the sites of C1q–APN complex deposition in various adipose tissues and blood vessels.

Results

Serum concentrations of C1q and HMW-APN and the C1q/HMW-APN ratio were independently associated with the severity of coronary stenosis. The amount of C1q–APN complex was significantly higher in patients with CAD compared with controls. C1q and APN co-localized in perivascular areas of subcutaneous, visceral, and pericardial fat tissues, and the internal mammary artery of patients with severe CAD.

Conclusions

Serum C1q concentration and the C1q/HMW-APN ratio were independent markers of coronary artery stenosis. The amount of C1q–APN complex was significantly greater in serum from CAD patients. C1q and APN co-localized to perivascular areas in adipose tissue and blood vessels. The association between the increased amount of the C1q–APN complex and CAD should be investigated further.

【 授权许可】

   
2015 Hong et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995; 15(5):551-561.
• [2]Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999; 340(2):115-126.
• [3]Syed Ikmal SI, Zaman Huri H, Vethakkan SR, Wan Ahmad WA. Potential biomarkers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery disease. Int J Endocrinol. 2013; 2013:698567.
• [4]Choi SH, Hong ES, Lim S. Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health. Front Endocrinol (Lausanne). 2013; 4:97.
• [5]Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al.. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257(1):79-83.
• [6]Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996; 271(18):10697-10703.
• [7]Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al.. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000; 20(6):1595-1599.
• [8]Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun. 2004; 315(2):264-271.
• [9]Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond). 2008; 114(5):361-374.
• [10]Schraw T, Wang ZV, Halberg N, Hawkins M, Scherer PE. Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology. 2008; 149(5):2270-2282.
• [11]Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006; 29(6):1357-1362.
• [12]Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006; 48(7):1369-1377.
• [13]Lim S, Koo BK, Cho SW, Kihara S, Funahashi T, Cho YM et al.. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis. 2008; 196(1):398-404.
• [14]Reid KB. Activation and control of the complement system. Essays Biochem. 1986; 22:27-68.
• [15]Schumaker VN, Zavodszky P, Poon PH. Activation of the first component of complement. Annu Rev Immunol. 1987; 5:21-42.
• [16]Arlaud GJ, Gaboriaud C, Thielens NM, Rossi V, Bersch B, Hernandez JF et al.. Structural biology of C1: dissection of a complex molecular machinery. Immunol Rev. 2001; 180:136-145.
• [17]Peake PW, Shen Y, Walther A, Charlesworth JA. Adiponectin binds C1q and activates the classical pathway of complement. Biochem Biophys Res Commun. 2008; 367(3):560-565.
• [18]Nakatsuji H, Kobayashi H, Kishida K, Nakagawa T, Takahashi S, Tanaka H et al.. Binding of adiponectin and C1q in human serum, and clinical significance of the measurement of C1q-adiponectin / total adiponectin ratio. Metabolism. 2013; 62(1):109-120.
• [19]Kishida K, Kishida N, Arima M, Nakatsuji H, Kobayashi H, Funahashi T et al.. Serum C1q- binding adiponectin in maintenance hemodialysis patients. BMC Nephrol. 2013; 14:50. BioMed Central Full Text
• [20]Hirata A, Kishida K, Nakatsuji H, Kobayashi H, Funahashi T, Shimomura I. High serum C1q-adiponectin/total adiponectin ratio correlates with coronary artery disease in Japanese type 2 diabetics. Metabolism. 2013; 62(4):578-585.
• [21]Choi EK, Choi SI, Rivera JJ, Nasir K, Chang SA, Chun EJ et al.. Coronary computed tomography angiography as a screening tool for the detection of occult coronary artery disease in asymptomatic individuals. J Am Coll Cardiol. 2008; 52(5):357-365.
• [22]Siegert CE, Kazatchkine MD, Sjoholm A, Wurzner R, Loos M, Daha MR. Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol. 1999; 116(1):4-8.
• [23]Lu JH, Teh BK, Wang L, Wang YN, Tan YS, Lai MC et al.. The classical and regulatory functions of C1q in immunity and autoimmunity. Cell Mol Immunol. 2008; 5(1):9-21.
• [24]Ghebrehiwet B, Hosszu KK, Valentino A, Peerschke EI. The C1q family of proteins: insights into the emerging non-traditional functions. Front Immunol. 2012; 3:52.
• [25]Hirata A, Kishida K, Kobayashi H, Nakatsuji H, Funahashi T, Shimomura I. Correlation between serum C1q-adiponectin/total adiponectin ratio and polyvascular lesions detected by vascular ultrasonography in Japanese type 2 diabetics. Metabolism. 2013; 62(3):376-385.
• [26]Kishida K, Nakagawa Y, Kobayashi H, Mazaki T, Yokoi H, Yanagi K et al.. High serum C1q-binding adiponectin levels in male patients with acute coronary syndrome. Cardiovasc Diabetol. 2014; 13:9. BioMed Central Full Text
• [27]Seldin MM, Tan SY, Wong GW. Metabolic function of the CTRP family of hormones. Rev Endocr Metab Disord. 2014; 15(2):111-123.
• [28]Choi KM, Hwang SY, Hong HC, Choi HY, Yoo HJ, Youn BS et al.. Implications of C1q/TNF-related protein-3 (CTRP-3) and progranulin in patients with acute coronary syndrome and stable angina pectoris. Cardiovasc Diabetol. 2014; 13:14. BioMed Central Full Text
• [29]Yuasa D, Ohashi K, Shibata R, Takeshita K, Kikuchi R, Takahashi R et al.. Association of circulating C1q/TNF-related protein 1 levels with coronary artery disease in men. PLoS One. 2014; 9(6):e99846.
• [30]Jung CH, Lee MJ, Kang YM, Jang JE, Leem J, Lee YL et al.. Association of serum C1q/TNF-related protein-9 concentration with arterial stiffness in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2014; 99(12):E2477-2484.
• [31]Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M et al.. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000; 32(2):47-50.
• [32]Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM et al.. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2004; 53(9):2473-2478.
• [33]Luo N, Liu J, Chung BH, Yang Q, Klein RL, Garvey WT et al.. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes. 2010; 59(4):791-799.
• [34]Ebina K, Oshima K, Matsuda M, Fukuhara A, Maeda K, Kihara S et al.. Adenovirus-mediated gene transfer of adiponectin reduces the severity of collagen-induced arthritis in mice. Biochem Biophys Res Commun. 2009; 378(2):186-191.